Agreement Between Large Language Model-Generated Treatment Recommendations With Guideline-Based and Tumor Board Decisions in Gastrointestinal Cancer (KITuKo)
Concordance of Large Language Model-Generated Treatment Recommendations With Multidisciplinary Tumor Board and Guideline-Based Decisions in Gastrointestinal Cancer: A Retrospective Cohort Study
The goal of this observational study is to learn whether a computer program can suggest cancer treatments that match expert recommendations for people with gastrointestinal cancer (cancer of the pancreas, stomach, or colon and rectum).
The main questions it aims to answer are:
- Do the treatment suggestions from the computer program match current medical guidelines?
- Do these suggestions match decisions made by a multidisciplinary tumor board (a team of cancer specialists)?
Researchers will review existing medical records from people who have already been treated for these cancers. They will enter key clinical information into a computer program that uses artificial intelligence (AI). The program will generate treatment suggestions for each case.
Researchers will then compare these suggestions with:
- guideline-based treatment recommendations
- decisions made by the tumor board
This study will help researchers understand whether AI tools could support doctors in making cancer treatment decisions in the future.
調査の概要
状態
詳細な説明
Gastrointestinal cancers require complex treatment planning that often involves surgery, systemic therapy, and multidisciplinary coordination. Clinical decision-making is typically guided by evidence-based recommendations and discussed in multidisciplinary tumor boards. However, the increasing complexity of treatment strategies and guideline frameworks can make consistent and reproducible decision-making challenging in routine clinical practice.
Recent advances in artificial intelligence have enabled the development of large language models (LLMs) that can process structured clinical information and generate text-based recommendations. These systems may offer a scalable approach to support clinical workflows, but their ability to produce reliable and clinically appropriate treatment suggestions in oncology remains uncertain.
This study evaluates the performance of an LLM-based system in the context of gastrointestinal oncology using retrospectively collected clinical case data. Structured case summaries derived from routine clinical documentation are used as standardized input. The model generates treatment recommendations under controlled conditions, allowing systematic comparison with established clinical reference standards.
The analysis focuses on the level of agreement between model-generated recommendations and established decision-making frameworks. In addition, the study explores how model performance varies across different clinical scenarios, including varying levels of disease complexity. Particular attention is given to situations in which recommendations differ, in order to better understand potential limitations of the model and identify patterns that may be clinically relevant.
Furthermore, the study examines the consistency of model outputs when the same clinical information is processed multiple times. This provides insight into the stability and reproducibility of the system, which are important considerations for potential real-world use.
The findings of this study are intended to inform the potential role of LLM-based tools as supportive systems in clinical decision-making. The study does not evaluate clinical outcomes or patient benefit, but instead focuses on agreement with established standards and expert-driven decisions as an initial step in assessing feasibility and safety.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Brandenburg
-
Brandenburg an der Havel、Brandenburg、ドイツ、14770
- University Hospital Brandenburg
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Histologically confirmed pancreatic, gastric, or colorectal adenocarcinoma
- Treatment discussed in a multidisciplinary tumor board
Exclusion Criteria:
- Non-adenocarcinoma histology
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
結腸直腸がん
結腸直腸がん患者
|
Detailed treatment recommendation according to the official guideline of the Association of the Scientific Medical Societies in Germany (AWMF; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften),
Structured clinical case summaries were analyzed by a GPT-4-class large language model to generate treatment recommendations.
Detailed treatment recommendation according to the case-specific postoperative tumor board review.
|
|
Pancreatic cancer
Patients with pancreatic cancer
|
Detailed treatment recommendation according to the official guideline of the Association of the Scientific Medical Societies in Germany (AWMF; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften),
Structured clinical case summaries were analyzed by a GPT-4-class large language model to generate treatment recommendations.
Detailed treatment recommendation according to the case-specific postoperative tumor board review.
|
|
Gastric cancer
Patients with gastric cancer
|
Detailed treatment recommendation according to the official guideline of the Association of the Scientific Medical Societies in Germany (AWMF; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften),
Structured clinical case summaries were analyzed by a GPT-4-class large language model to generate treatment recommendations.
Detailed treatment recommendation according to the case-specific postoperative tumor board review.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Concordance with guideline-based management
時間枠:At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
|
Agreement between LLM-generated recommendations and AWMF guideline-supported treatment strategies
|
At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Concordance with multidisciplinary tumor board decisions
時間枠:At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
|
Agreement between LLM-generated recommendations and tumor board treatment strategies
|
At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
|
|
Reproducibility of LLM recommendations across repeated runs
時間枠:At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
|
Structured clinical case vignettes were entered into ChatGPT using a standardized prompt template.
To assess within-model reproducibility, each clinical vignette was analyzed in 3 independent model sessions performed on different days using identical clinical input.
|
At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
|
|
Characterization of discordant recommendations (e.g., overtreatment, undertreatment)
時間枠:At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
|
Overtreatment was defined as an LLM-generated recommendation exceeding the intensity of the reference recommendation. Undertreatment was defined as omission of a recommended treatment or recommendation of a less intensive strategy. |
At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- KITuKo
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。